期刊
ANTIMICROBIAL THERAPEUTICS REVIEWS: ANTIBIOTICS THAT TARGET THE RIBOSOME
卷 1241, 期 -, 页码 153-161出版社
BLACKWELL SCIENCE PUBL
DOI: 10.1111/j.1749-6632.2011.06300.x
关键词
drug development; antibacterial; Ketek; FDA guidelines
The antibiotic telithromycin (Ketek, Sanofi-aventis) had two of three treatment indications withdrawn after post-marketing reports of serious and fatal adverse events. The rationale for the withdrawal of specific indications (acute bacterial sinusitis and acute exacerbations of chronic bronchitis), while permitting the drug to remain available for the treatment of community-acquired pneumonia, focused on the lack of demonstrated efficacy from clinical trials that included an active control to which the investigational drug, telethromycin, was determined to be statistically noninferior. This action regarding telithromycin represents a reversal of previous FDA guidelines for the conduct of clinical trials for antibacterial treatment indications and has increased the regulatory risk for future drug development. New clinical trial guidelines have been published that will increase the time and resources required to achieve regulatory marketing approval. This paper reviews recent regulatory actions and discusses the impact these new guidelines will have on future antibacterial clinical trial designs and challenges.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据